Loading...
•
Sep 30
Annovis Bio Q3 2025 Earnings Report
Annovis Bio narrowed its net loss and reported increased R&D spending in Q3 2025 as it advanced its pivotal Alzheimer's study.
Key Takeaways
Annovis Bio posted a net loss of $7.26 million in Q3 2025, a significant improvement from $12.64 million in the same period last year. R&D expenses rose sharply as the company progressed its Phase 3 Alzheimer's trial, while G&A costs declined.
Net loss decreased to $7.26 million from $12.64 million in Q3 2024
R&D expenses increased to $6.3 million as trials ramped up
Cash and equivalents rose to $15.3 million, boosted by recent offerings
Basic and diluted EPS improved to -$0.37 from -$0.97 last year
Annovis Bio
Annovis Bio
Forward Guidance
Annovis expects to continue funding operations through Q3 2026, focusing on Phase 3 Alzheimer's trial completion and NDA preparation.
Positive Outlook
- Full activation of 84 sites in pivotal Alzheimer's Phase 3 trial
- First patients completed 6-month treatment in Phase 3
- Encouraging biomarker results from Phase 2/3 study
- Strengthened IP with patent transfer to new crystal form
- Raised $9.4M in new capital through direct offerings
Challenges Ahead
- No reported revenue to offset R&D costs
- Increased R&D spend widened operating losses
- Ongoing net losses despite lower G&A expenses
- Reliance on external funding to support operations
- Regulatory success and trial outcomes still pending